OLINK PROTEOMICS INC

OLINK PROTEOMICS INC specializes in high-sensitivity proteomic analysis and precision biomarker detection using proprietary OLINK platforms, delivering targeted protein quantification services for complex biological samples including plasma, bronchoalveolar lavage, and tissue extracts. Their core capabilities center on multiplex immunoassay technologies, particularly the OLINK TARGET and SPRINT platforms, enabling simultaneous measurement of dozens of cytokines, immune regulators, and disease-associated proteins with sub-picomolar precision. The company manufactures and supports specialized reagent kits, detection systems, and analytical instrumentation for clinical and research laboratories, with deep expertise in immunoassay validation, sample preparation workflows, and data interpretation for translational medicine applications. Their technical differentiation lies in the integration of proximity extension assay (PEA) technology, which offers superior specificity and dynamic range compared to traditional ELISA methods, making them a preferred provider for biomarker discovery and validation in oncology, cardiotoxicity, and critical care research. The contractor maintains a dominant relationship with the Department of Health and Human Services, consistently providing proteomic assay services, reagent supply, and instrument maintenance to NIH institutes, CDC centers, and other HHS components engaged in infectious disease, cancer, and immunology research. Work for the Department of Defense is limited but includes support for military medical research initiatives requiring high-throughput protein profiling. Industry focus is firmly rooted in proteomics and biotechnology, with primary activity in testing laboratories, biological product manufacturing, and in-vitro diagnostic substance production. The firm serves the translational research and clinical diagnostics verticals, bridging academic discovery with regulatory-ready assay development. OLINK PROTEOMICS INC is a small business headquartered in Waltham, Massachusetts, with no federal certifications on record. Their geographic presence is concentrated in the Boston biotech corridor, positioning them as a specialized supplier to federally funded life sciences research programs requiring advanced proteomic capabilities.